FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02328300|
Recruitment Status : Withdrawn (FLT production not available)
First Posted : December 31, 2014
Last Update Posted : November 14, 2018
|Condition or disease||Intervention/treatment|
|Brain Lesions Brain Metastasis Brain Metastases||Drug: FLT PET/MR|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions|
|Actual Study Start Date :||May 7, 2014|
|Actual Primary Completion Date :||July 31, 2018|
|Actual Study Completion Date :||July 31, 2018|
All participants will have known brain lesion in the central nervous system (CNS) scheduled to have surgical biopsy of the lesion, identified by the UNC Brain Tumor Board and will have the clinical question of radiation necrosis vs. recurrence.
All participants will receive a FLT PET/MR scan.
Drug: FLT PET/MR
Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
Other Name: FLT PET/MRI
- Sensitivity and specificity of FLT-PET-MRI in distinguishing between recurrence and radiation necrosis, with surgical biopsy as gold standard [ Time Frame: 1 week post-surgical biopsy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02328300
|United States, North Carolina|
|University of North Carolina-Chapel Hill|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||Yueh Lee, MD/PhD||University of North Carolina, Chapel Hill|